Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Response Genetics Inc Com (NASDAQOTCBB:RGDXQ)

CAPS Rating: No stars

The Company is engaged in the research and development of its own pharmacogenomic cancer diagnostic tests based on its proprietary technologies.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

10 Outperform
0 Underperform
 

All-Star Players

2 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTCBB:RGDXQ Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

Recent Community Commentary

Read the most recent pitches from players about RGDXQ.

Recs

0
Member Avatar CRAZYCAPTAIN (94.15) Submitted: 7/16/2007 9:24:54 AM : Outperform Start Price: $7.13 NASDAQ OTC:RGDXQ Score: -319.26

Growing pharmacogenomics services. RGDX is leveraging its unique RGI-I and RGI-II technologies in addition to sample processing expertise and big pharmaceutical relationships to grow its pharmacogenomic testing services business.

Large new GSK contract driving near-term growth. The Company entered into a laboratory services agreement with GSK (NR) in Dec06 for gene expression services. It is associated with a large clinical trial that is expected to begin in late 2007, and could ultimately be worth $28 million to RGDX over three years.

Service business helping fund Dx. RGDX is developing a cancer diagnostics business which will partially be funded by the pharmaceutical services business and proceeds from its $21MM IPO.

ERCC1 marker data promising for Dx. Recent disclosure of prospective Phase III data suggest it may be feasible to determine a less toxic and more effective non-small cell lung cancer regimen based on ERCC1 expression data. This area could be worth greater than $200MM annually.

Valuation. The diagnostics opportunity, while difficult to quantify today, may represent a significant long-term growth driver for RGDX. Shares are currently trading at 4.1 times 2008 sales versus 5.6 times for the molecular diagnostic peer group. Our 12 month price target is $7.50 (suggests 30% upside from current levels), based on a 2008 sales multiple of 5.3 times, discounted slightly versus the peers for the lower margin services business concentration.

Leaderboard

Find the members with the highest scoring picks in RGDXQ.

Score Leader

TMFJoeyRockets

TMFJoeyRockets (99.97) Score: +41.47

The Score Leader is the player with the highest score across all their picks in RGDXQ.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
JStine25 22.91 7/23/2014 Outperform 3M $0.82 -99.67% +128.72% -228.39 0 Comment
rbuscho < 20 7/1/2014 Outperform 5Y $0.90 -99.70% +131.40% -231.10 0 Comment
gfischer13 26.74 6/2/2014 Outperform 5Y $0.95 -99.72% +135.67% -235.38 0 Comment
studentprince1 43.14 6/4/2014 Outperform 5Y $0.95 -99.72% +135.88% -235.59 0 Comment
halvedcaps < 20 6/4/2014 Outperform 5Y $0.95 -99.72% +135.88% -235.59 0 Comment
sherwolf 89.61 3/26/2014 Outperform 3Y $1.11 -99.76% +143.20% -242.95 0 Comment
laugef 33.36 9/23/2013 Outperform 5Y $2.25 -99.88% +166.29% -266.17 0 Comment
bswolf 69.48 8/8/2013 Outperform 5Y $2.25 -99.88% +167.08% -266.96 0 Comment
JumperLee 21.32 6/6/2007 Outperform 3Y $7.11 -99.96% +213.89% -313.86 0 Comment
CRAZYCAPTAIN 94.15 6/12/2007 Outperform 3Y $7.13 -99.96% +219.30% -319.26 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for RGDXQ.